Skip to content
HowShorted

SpringWorks Therapeutics, Inc. short interest in 2020

In 2020, SpringWorks Therapeutics, Inc.'s disclosed short interest ran from 2.97% of shares outstanding on 15 Jan 2020 to 7.21% on 31 Dec 2020, a change of +4.24 percentage points. The year's high was 7.33% on 30 Sep 2020 and its low 2.49% on 13 Mar 2020, averaging 4.82% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.37 days on 15 Apr 2020. Full history: SpringWorks Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for SpringWorks Therapeutics, Inc. in 2020

2020 in figures

Start of year
2.97% (15 Jan 2020)
End of year
7.21% (31 Dec 2020)
Change
+4.24 pp
High
7.33% (30 Sep 2020)
Low
2.49% (13 Mar 2020)
Average
4.82%
Highest days to cover
25.37 (15 Apr 2020)
SEC filings marked
8

Every report in 2020

SpringWorks Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20202.97%9.34
31 Jan 20202.81%15.48
14 Feb 20202.70%20.87
28 Feb 20202.70%12.95
13 Mar 20202.49%5.2410-K filed, results (8-K)
31 Mar 20203.99%10.10
15 Apr 20204.51%25.37
30 Apr 20204.42%20.48
15 May 20204.23%11.0410-Q filed, results (8-K)
29 May 20203.83%12.75
15 Jun 20203.97%12.90
30 Jun 20204.96%5.07
15 Jul 20204.82%16.94
31 Jul 20204.87%11.71
14 Aug 20205.04%20.7710-Q filed, results (8-K)
31 Aug 20205.31%15.45
15 Sep 20205.34%11.43
30 Sep 20207.33%8.37
15 Oct 20206.55%4.72
30 Oct 20206.97%16.83
13 Nov 20206.25%7.6110-Q filed, results (8-K)
30 Nov 20206.41%13.51
15 Dec 20206.06%11.71
31 Dec 20207.21%9.39

See also: SpringWorks Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.